Vivos Inc. Reports Revenue Increase to $27,995 but Continues to Operate at a Loss

Vivos Inc. reported a modest increase in revenue for the fiscal year ending December 31, 2024, generating $27,995 compared to $19,500 in 2023. The company continues to operate at a loss, with a net loss of $2,910,448 for 2024, slightly higher than the previous year's loss of $2,894,753. The increase in revenue is attributed primarily to the procedures performed with its IsoPet® therapies, along with a new licensing fee charged to clinics for certification to perform these therapies. Despite the revenue growth, the company reported a gross loss of $2,984, reflecting the costs associated with goods sold, which totaled $30,979.

In terms of operational changes, Vivos Inc. has expanded its IsoPet certified clinics from four in 2023 to thirteen by the end of 2024, with plans to open approximately ten more clinics in 2025. The company has also restructured its internal resources to align with its focus on both animal and human therapy applications. The FDA granted its RadioGel™ device designation as a Breakthrough Device in December 2023, allowing for expedited review processes, which the company is leveraging to address FDA inquiries and prepare for clinical trials in India.

The company’s operational expenses decreased to $2,601,400 in 2024 from $2,787,110 in 2023, primarily due to reduced research and development costs as the company shifted focus towards commercialization. However, professional fees increased as the company engaged more consultants to assist with its Regulation A+ offering. Vivos Inc. reported a working capital of $2,147,247 as of December 31, 2024, an increase from $1,365,120 in the previous year, indicating improved liquidity despite ongoing operational losses.

Looking ahead, Vivos Inc. anticipates needing approximately $10 million over the next three years to fund clinical trials, activate regional clinics, and establish an independent production center. The company has expressed concerns regarding its ability to continue as a going concern, as it has relied heavily on investor funding and has accumulated significant losses since inception. The company plans to pursue additional capital through strategic transactions and partnerships, although it acknowledges the uncertainty surrounding its ability to secure such funding.

Overall, Vivos Inc. is navigating a challenging financial landscape while making strides in expanding its market presence and preparing for future clinical applications of its products. The company remains focused on its dual strategy of developing its veterinary and human therapy markets, with the hope that successful clinical trials and product adoption will lead to sustainable revenue growth in the future.